Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Broad antibacterial spectrum, high oral bioavailability and excellent tissue penetration combined with safety and few, yet rare, unwanted effects, have made the quinolones class of antimicrobials one of the most used in inpatients and outpatients. Initially discovered during the search for improved chloroquine-derivative molecules with increased anti-malarial activity, today the quinolones, intended as antimicrobials, comprehend four generations that progressively have been extending antimicrobial spectrum and clinical use. The quinolone class of antimicrobials exerts its antimicrobial actions through inhibiting DNA gyrase and Topoisomerase IV that in turn inhibits synthesis of DNA and RNA. Good distribution through different tissues and organs to treat Gram-positive and Gram-negative bacteria have made quinolones a good choice to treat disease in both humans and animals. The extensive use of quinolones, in both human health and in the veterinary field, has induced a rise of resistance and menace with leaving the quinolones family ineffective to treat infections. This review revises the evolution of quinolones structures, biological activity, and the clinical importance of this evolving family. Next, updated information regarding the mechanism of antimicrobial activity is revised. The veterinary use of quinolones in animal productions is also considered for its environmental role in spreading resistance. Finally, considerations for the use of quinolones in human and veterinary medicine are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Common Mechanism of Cellular Death Induced by Bactericidal Antibiotics
Kohanski, M. A., Dwyer, D. J., Hayete, B., Lawrence, C. A., & Collins, J. J. (2007) · Cell · doi:10.1016/j.cell.2007.06.049 · Cited by 2,982
Mechanism of Quinolone Action and Resistance
Aldred, K. J., Kerns, R. J., & Osheroff, N. (2014) · Biochemistry · doi:10.1021/bi5000564 · Cited by 1,282
Novel HIV-1 Integrase Inhibitors Derived from Quinolone Antibiotics
Sato, M., Motomura, T., Aramaki, H., Matsuda, T., Yamashita, M., Ito, Y., Kawakami, H., Matsuzaki, Y., Watanabe, W., Yamataka, K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0600139 · Cited by 328
Wang, Z., Hu, J., Yang, X., Feng, X., Li, X., Huang, L., & Chan, A. S. C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01417 · Cited by 91 · cited 1×
“(As Anti-Cancer/Anti-Tumor) Moxifloxacin Activity anti-tumor (Cooper complexes) [119] Ciprofloxacin and other FQs Cell cycle arrest and induction of apoptosis [115–117] Ruthenium complex with quinolones Anti-cancer [126] (With Other Effects) Enrofloxacin, ofloxacin, orbifloxacin, ciprofloxacin Inhibitory effects on CY…”
Background
Research works printed but not linked: 305
- Price, 1949, Alkaloids of the Australian Rutaceae: Melicope fareana. I. Isolation of the Constituent Alkaloids, Aust. J. Chem., 2, 249, 10.1071/CH9490249 · doi:10.1071/ch9490249
- Drummond, 1949, Alkaloids of the Australian Rutaceae: Acronychia baueri. III. The Structure of Acronycine, Aust. J. Chem., 2, 630, 10.1071/CH9490630 · doi:10.1071/ch9490630
- Crow, 1949, Alkaloids of the Australian Rutaceae: Melicope fareana. V. The Structure of the Alkaloids, Aust. J. Chem., 2, 282, 10.1071/CH9490282 · doi:10.1071/ch9490282
- Bisacchi, 2015, Origins of the Quinolone Class of Antibacterials: An Expanded “Discovery Story”, J. Med. Chem., 58, 4874, 10.1021/jm501881c · DOI · Paper page
- Mitscher, 2005, Bacterial Topoisomerase Inhibitors: Quinolone and Pyridone Antibacterial Agents, Chem. Rev., 105, 559, 10.1021/cr030101q · DOI · Paper page
- Redgrave, 2014, Fluoroquinolone Resistance: Mechanisms, Impact on Bacteria, and Role in Evolutionary Success, Trends Microbiol., 22, 438, 10.1016/j.tim.2014.04.007 · DOI · Paper page
- Andersson, 2003, Development of the Quinolones, J. Antimicrob. Chemother., 51, 1, 10.1093/jac/dkg212 · DOI
- Mandell, 2002, Safety of Fluoroquinolones: An Update, Can. J. Infect. Dis., 13, 54
- Nagaoka, S. (2019). Drug Discovery in Japan: Investigating the Sources of Innovation, Springer. · doi:10.1007/978-981-13-8906-1
- Pavithra, 2010, PK-PD Modelling of Norfloxacin after Oral Administration in Rabbits, Vet. World, 3, 546
- Appelbaum, 1999, Quinolone Activity Against Anaerobes, Drugs, 58, 60, 10.2165/00003495-199958002-00012 · DOI
- Prabhala, 1984, In Vitro Susceptibility of Anaerobic Bacteria to Ciprofloxacin (Bay o 9867), Antimicrob. Agents Chemother., 26, 785, 10.1128/AAC.26.5.785 · doi:10.1128/aac.26.5.785
- Goldstein, 1992, Comparative Activity of Ciprofloxacin, Ofloxacin, Sparfloxacin, Temafloxacin, CI-960, CI-990, and WIN 57273 against Anaerobic Bacteria, Antimicrob. Agents Chemother., 36, 1158, 10.1128/AAC.36.5.1158 · doi:10.1128/aac.36.5.1158
- Naeem, A., Badshah, S.L., Muska, M., Ahmad, N., and Khan, K. (2016). The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity. Molecules, 21. · DOI · Paper page
- King, 2000, New Classification and Update on the Quinolone Antibiotics, Am. Fam. Physician, 61, 2741
- Wexler, 1994, In Vitro Activity of DU-6859a against Anaerobic Bacteria, Antimicrob. Agents Chemother., 38, 2504, 10.1128/AAC.38.10.2504 · doi:10.1128/aac.38.10.2504
- Balwan, 2015, Clinafloxacin for Treatment of Burkholderia Cenocepacia Infection in a Cystic Fibrosis Patient, Antimicrob. Agents Chemother., 60, 1, 10.1128/AAC.01428-15 · DOI
- Lauderdale, 2010, Comparative In Vitro Activities of Nemonoxacin (TG-873870), a Novel Nonfluorinated Quinolone, and Other Quinolones against Clinical Isolates, Antimicrob. Agents Chemother., 54, 1338, 10.1128/AAC.01197-09 · doi:10.1128/aac.01197-09
- Stubbings, 2009, New Antibiotics for Antibiotic-Resistant Bacteria, F1000 Biol. Rep., 1, 40, 10.3410/B1-40 · doi:10.3410/b1-40
- Roychoudhury, 2001, Activity of Non-Fluorinated Quinolones (NFQs) against Quinolone-Resistant Escherichia coli and Streptococcus pneumoniae, J. Antimicrob. Chemother., 48, 29, 10.1093/jac/48.1.29 · DOI
- Adam, 2009, In Vitro Activity of Nemonoxacin, a Novel Nonfluorinated Quinolone, against 2440 Clinical Isolates, Antimicrob. Agents Chemother., 53, 4915, 10.1128/AAC.00078-09 · doi:10.1128/aac.00078-09
- Qin, 2014, Review of Nemonoxacin with Special Focus on Clinical Development, Drug Des. Dev. Ther., 8, 765
- Borges, 2013, Antibacterial Activity and Mode of Action of Ferulic and Gallic Acids Against Pathogenic Bacteria, Microb. Drug Resist., 19, 256, 10.1089/mdr.2012.0244 · DOI · Paper page
- Ibitoye, 2019, Ferulic Acid Potentiates the Antibacterial Activity of Quinolone-Based Antibiotics against Acinetobacter baumannii, Microb. Pathog., 126, 393, 10.1016/j.micpath.2018.11.033 · DOI
- Courtney, 2017, Potentiating Antibiotics in Drug-Resistant Clinical Isolates via Stimuli-Activated Superoxide Generation, Sci. Adv., 3, e1701776, 10.1126/sciadv.1701776 · DOI
- Neu, 1991, Synergy and Antagonism of Combinations with Quinolones, Eur. J. Clin. Microbiol. Infect. Dis., 10, 255, 10.1007/BF01966998 · doi:10.1007/bf01966998
- Tintino, S.R., de Souza, V.C.A., da Silva, J.M.A., Oliveira-Tintino, C.D.d.M., Pereira, P.S., Leal-Balbino, T.C., Pereira-Neves, A., Siqueira-Junior, J.P., da Costa, J.G.M., and Rodrigues, F.F.G. (2020). Effect of Vitamin K3 Inhibiting the Function of NorA Efflux Pump and Its Gene Expression on Staphylococcus aureus. Membranes, 10. · DOI
- Lim, 2019, Identification of a Potent Small-Molecule Inhibitor of Bacterial DNA Repair That Potentiates Quinolone Antibiotic Activity in Methicillin-Resistant Staphylococcus aureus, Bioorgan. Med. Chem., 27, 114962, 10.1016/j.bmc.2019.06.025 · DOI
- Wilkinson, 2016, Structural Basis for the Inhibition of RecBCD by Gam and Its Synergistic Antibacterial Effect with Quinolones, eLife, 5, e22963, 10.7554/eLife.22963 · DOI
- Liu, 2009, Synergistic Effect of Kaempferol Glycosides Purified from Laurus Nobilis and Fluoroquinolones on Methicillin-Resistant Staphylococcus aureus, Biol. Pharm. Bull., 32, 489, 10.1248/bpb.32.489 · DOI
- Cannalire, 2017, Natural Isoflavone Biochanin A as a Template for the Design of New and Potent 3-Phenylquinolone Efflux Inhibitors against Mycobacterium avium, Eur. J. Med. Chem., 140, 321, 10.1016/j.ejmech.2017.09.014 · DOI
- Duan, 2016, L-Serine Potentiates Fluoroquinolone Activity against Escherichia Coli by Enhancing Endogenous Reactive Oxygen Species Production, J. Antimicrob. Chemother., 71, 2192, 10.1093/jac/dkw114 · DOI
- Wang, 2020, Palmatine Is a Plasmid-Mediated Quinolone Resistance (PMQR) Inhibitor That Restores the Activity of Ciprofloxacin Against QnrS and AAC(6ʹ)-Ib-Cr-Producing Escherichia coli, Infect. Drug Resist., 13, 749, 10.2147/IDR.S242304 · DOI
- Bradfute, S.B., Ye, C., Clarke, E.C., Kumar, S., Timmins, G.S., and Deretic, V. (2020). Ambroxol and Ciprofloxacin Show Activity Against SARS-CoV2 in Vero E6 Cells at Clinically-Relevant Concentrations. bioRxiv. · DOI
- Wei, 2017, Activity of Levofloxacin in Combination with Colistin against Acinetobacter baumannii: In Vitro and in a Galleria mellonella Model, J. Microbiol. Immunol. Infect., 50, 821, 10.1016/j.jmii.2015.10.010 · doi:10.1016/j.jmii.2015.10.010
- Gorityala, 2015, Adjuvants Based on Hybrid Antibiotics Overcome Resistance in Pseudomonas aeruginosa and Enhance Fluoroquinolone Efficacy, Angew. Chem. Int. Ed. Engl., 55, 555, 10.1002/anie.201508330 · DOI
- Gorityala, 2016, Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux, J. Med. Chem., 59, 8441, 10.1021/acs.jmedchem.6b00867 · DOI
- Domalaon, 2018, Antibiotic Hybrids: The Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?, Clin. Microbiol. Rev., 31, e00077-17, 10.1128/CMR.00077-17 · DOI · Paper page
- Park, 2002, Physicochemical Properties of Quinolone Antibiotics in Various Environments, Eur. J. Med. Chem., 37, 443, 10.1016/S0223-5234(02)01361-2 · DOI · Paper page
- Ross, 1992, Physicochemical Properties of the Fluoroquinolone Antimicrobials. II. Acid Ionization Constants and Their Relationship to Structure, Int. J. Pharm., 83, 267, 10.1016/0378-5173(82)90032-1 · doi:10.1016/0378-5173(82)90032-1
- Cramariuc, 2012, Mechanism for Translocation of Fluoroquinolones across Lipid Membranes, Biochim. Biophys. Acta BBA Biomembr., 1818, 2563, 10.1016/j.bbamem.2012.05.027 · DOI
- 2015, Delafloxacin, a Non-Zwitterionic Fluoroquinolone in Phase III of Clinical Development: Evaluation of Its Pharmacology, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy, Future Microbiol., 10, 1111, 10.2217/fmb.15.39 · doi:10.2217/fmb.15.39
- Lodise, 2018, Safety of Delafloxacin: Focus on Adverse Events of Special Interest, Open Forum Infect. Dis., 5, ofy220, 10.1093/ofid/ofy220 · DOI
- Rusu, A., Lungu, I.-A., Moldovan, O.-L., Tanase, C., and Hancu, G. (2021). Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones—Shaping the Fifth Generation. Pharmaceutics, 13. · DOI
- Biernacka, 2014, Experimental and Theoretical Studies on the Molecular Properties of Ciprofloxacin, Norfloxacin, Pefloxacin, Sparfloxacin, and Gatifloxacin in Determining Bioavailability, J. Biol. Phys., 40, 335, 10.1007/s10867-014-9354-z · DOI
- Biernacka, 2014, Physicochemical Properties of Lomefloxacin, Levofloxacin, and Moxifloxacin Relevant to the Biopharmaceutics Classification System, Acta Chim. Slov., 61, 827
- Uivarosi, 2013, Metal Complexes of Quinolone Antibiotics and Their Applications: An Update, Molecules, 18, 11153, 10.3390/molecules180911153 · DOI
- Ross, 1993, Physicochemical Properties of the Fluoroquinolone Antimicrobials V. Effect of Fluoroquinolone Structure and PH on the Complexation of Various Fluoroquinolones with Magnesium and Calcium Ions, Int. J. Pharm., 93, 121, 10.1016/0378-5173(93)90170-K · doi:10.1016/0378-5173(93)90170-k
- Pitman, S.K., Hoang, U.T.P., Wi, C.H., Alsheikh, M., Hiner, D.A., and Percival, K.M. (2019). Revisiting Oral Fluoroquinolone and Multivalent Cation Drug-Drug Interactions: Are They Still Relevant?. Antibiotics, 8. · doi:10.3390/antibiotics8030108
- Stass, 2001, Effects of Iron Supplements on the Oral Bioavailability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, in Humans, Clin. Pharm., 40, 57, 10.2165/00003088-200140001-00008 · doi:10.2165/00003088-200140001-00008
- Djurdjevic, 2014, The Effect of Some Fluoroquinolone Family Members on Biospeciation of Copper(II), Nickel(II) and Zinc(II) Ions in Human Plasma, Molecules, 19, 12194, 10.3390/molecules190812194 · DOI
- Wang, 2020, Dynamic Interaction of Fluoroquinolones with Magnesium Ions Monitored Using Bacterial Outer Membrane Nanopores, Chem. Sci., 11, 10344, 10.1039/D0SC03486J · DOI
- Valisena, 1990, Relevance of Ionic Effects on Norfloxacin Uptake by Escherichia coli, Biochem. Pharmacol., 40, 431, 10.1016/0006-2952(90)90540-2 · doi:10.1016/0006-2952(90)90540-2
- Mortimer, 1991, A comparison of methods used for measuring the accumulation of quinolones by Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus, J. Antimicrob. Chemother., 28, 639, 10.1093/jac/28.5.639 · doi:10.1093/jac/28.5.639
- Furet, 1992, Transport of Pefloxacin across the Bacterial Cytoplasmic Membrane in Quinolone-Susceptible Staphylococcus aureus, Antimicrob. Agents Chemother., 36, 2506, 10.1128/AAC.36.11.2506 · doi:10.1128/aac.36.11.2506
- Ross, 1992, Physicochemical Properties of the Fluoroquinolone Antimicrobials. III. 1-Octanol/Water Partition Coefficients and Their Relationships to Structure, Int. J. Pharm., 88, 379, 10.1016/0378-5173(92)90336-Z · doi:10.1016/0378-5173(92)90336-z
- Ferreira, M., Bessa, L.J., Sousa, C.F., Eaton, P., Bongiorno, D., Stefani, S., Campanile, F., and Gameiro, P. (2020). Fluoroquinolone Metalloantibiotics: A Promising Approach against Methicillin-Resistant Staphylococcus aureus. Int. J. Environ. Res. Public Health, 17. · DOI
- Feio, 2014, Fluoroquinolone–Metal Complexes: A Route to Counteract Bacterial Resistance?, J. Inorg. Biochem., 138, 129, 10.1016/j.jinorgbio.2014.05.007 · DOI
- Yang, S., Tian, M., Yuan, L., Deng, H., Wang, L., Li, A., Hou, Z., Li, Y., and Zhang, Y. (2020, September 25). Analysis of E. rutaecarpa Alkaloids Constituents In Vitro and In Vivo by UPLC-Q-TOF-MS Combined with Diagnostic Fragment. Available online: https://www.hindawi.com/journals/jamc/2016/4218967/. · doi:10.1155/2016/4218967
- Heeb, 2011, Quinolones: From Antibiotics to Autoinducers, FEMS Microbiol. Rev., 35, 247, 10.1111/j.1574-6976.2010.00247.x · DOI · Paper page
- Dekker, 1998, New Quinolone Compounds from Pseudonocardia Sp. with Selective and Potent Anti-Helicobacter pylori Activity: Taxonomy of Producing Strain, Fermentation, Isolation, Structural Elucidation and Biological Activities, J. Antibiot., 51, 145, 10.7164/antibiotics.51.145 · DOI
- Geddis, 2018, Synthesis and Biological Evaluation of 1,2-Disubstituted 4-Quinolone Analogues of Pseudonocardia Sp. Natural Products, Beilstein J. Org. Chem., 14, 2680, 10.3762/bjoc.14.245 · doi:10.3762/bjoc.14.245
- Jucker, E. (1977). Development of antibacterial agents of the nalidixic acid type. Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrès des Rechersches Pharmaceutiques, Birkhäuser. · doi:10.1007/978-3-0348-7098-6
- Schaumann, 2006, Activities of Quinolones Against Obligately Anaerobic Bacteria, Anti Infect. Agents Med. Chem., 6, 49, 10.2174/187152107779314179 · doi:10.2174/187152107779314179
- Bryskier, A. (2005). Antimicrobial Agents: Antibacterials and Antifungals, ASM Press. · DOI · Paper page
- Domagala, 1994, Structure-Activity and Structure-Side-Effect Relationships for the Quinolone Antibacterials, J. Antimicrob. Chemother., 33, 685, 10.1093/jac/33.4.685 · DOI · Paper page
- Takahashi, 2003, The history of the development and changes of quinolone antibacterial agents, Yakushigaku Zasshi, 38, 161
- Emmerson, 2003, The Quinolones: Decades of Development and Use, J. Antimicrob. Chemother., 51, 13, 10.1093/jac/dkg208 · DOI · Paper page
- Rohlfing, 1976, Bioevaluation of the Antibacterial Flumequine for Urinary Tract Use, Antimicrob. Agents Chemother., 10, 20, 10.1128/AAC.10.1.20 · doi:10.1128/aac.10.1.20
- Wise, 1983, In Vitro Activity of Bay 09867, a New Quinoline Derivative, Compared with Those of Other Antimicrobial Agents, Antimicrob. Agents Chemother., 23, 559, 10.1128/AAC.23.4.559 · doi:10.1128/aac.23.4.559
- Chin, 1984, Ciprofloxacin, a Quinolone Carboxylic Acid Compound Active against Aerobic and Anaerobic Bacteria, Antimicrob. Agents Chemother., 25, 319, 10.1128/AAC.25.3.319 · doi:10.1128/aac.25.3.319
- Hoshino, 1989, Inhibitory Effects of Quinolones on DNA Gyrase of Escherichia coli and Topoisomerase II of Fetal Calf Thymus, Antimicrob. Agents Chemother., 33, 1816, 10.1128/AAC.33.10.1816 · DOI
- Shah, 2007, The Role of Fluorine in Medicinal Chemistry, J Enzym. Inhib. Med. Chem., 22, 527, 10.1080/14756360701425014 · DOI · Paper page
- Sato, 1982, In Vitro and in Vivo Activity of DL-8280, a New Oxazine Derivative, Antimicrob. Agents Chemother., 22, 548, 10.1128/AAC.22.4.548 · doi:10.1128/aac.22.4.548
- Woodcock, 1997, In Vitro Activity of BAY 12-8039, a New Fluoroquinolone, Antimicrob. Agents Chemother., 41, 101, 10.1128/AAC.41.1.101 · DOI · Paper page
- Lu, 2001, Enhancement of Fluoroquinolone Activity by C-8 Halogen and Methoxy Moieties: Action against a Gyrase Resistance Mutant of Mycobacterium smegmatis and a Gyrase-Topoisomerase IV Double Mutant of Staphylococcus aureus, Antimicrob. Agents Chemother., 45, 2703, 10.1128/AAC.45.10.2703-2709.2001 · doi:10.1128/aac.45.10.2703-2709.2001
- Ruiz, 2019, Transferable Mechanisms of Quinolone Resistance from 1998 Onward, Clin. Microbiol. Rev., 32, e00007-19, 10.1128/CMR.00007-19 · DOI
- Klomp, F., Wenzel, C., Drozdzik, M., and Oswald, S. (2020). Drug–Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes. Pharmaceutics, 12. · DOI
- Bridle, 2017, Computational Study of Fluoroquinolone Binding to Mg(H2O)N2+ and Its Applicability to Future Drug Design, Int. J. Quantum Chem., 117, e25428, 10.1002/qua.25428 · doi:10.1002/qua.25428
- Panda, 2015, Novel Antibacterial Active Quinolone–Fluoroquinolone Conjugates and 2D-QSAR Studies, Bioorgan. Med. Chem. Lett., 25, 3816, 10.1016/j.bmcl.2015.07.077 · DOI
- Hou, Y., Zhao, Y., and Li, Y. (2020). Environmentally Friendly Fluoroquinolone Derivatives with Lower Plasma Protein Binding Rate Designed Using 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation. Int. J. Environ. Res. Public Health, 17. · doi:10.3390/ijerph17186626
- Zhao, 2019, Combined QSAR/QSPR and Molecular Docking Study on Fluoroquinolones to Reduce Biological Enrichment, Comput. Biol. Chem., 79, 177, 10.1016/j.compbiolchem.2019.02.008 · doi:10.1016/j.compbiolchem.2019.02.008
- (2021, October 28). Molecular Design of Lower Photodegradation Fluoroquinolone Antibiotics and Their Photolysis Paths Inference. Available online: http://www.cjcu.jlu.edu.cn/EN/10.7503/cjcu20180475. · doi:10.7503/cjcu20180475
- Sass, 2017, Computer-Aided Drug Design Methods, Antibiotics, Volume 1520, 85, 10.1007/978-1-4939-6634-9_5 · DOI · Paper page
- Sarma, 1989, Norfloxacin: A New Drug in the Treatment of Falciparum Malaria, Ann. Intern. Med., 111, 336, 10.7326/0003-4819-111-4-336 · doi:10.7326/0003-4819-111-4-336
- Tripathi, 1993, Curative Efficacy of Norfloxacin in Falciparum Malaria, Indian J. Med. Res., 97, 176
- Dalhoff, 2015, Antiviral, Antifungal, and Antiparasitic Activities of Fluoroquinolones Optimized for Treatment of Bacterial Infections: A Puzzling Paradox or a Logical Consequence of Their Mode of Action?, Eur. J. Clin. Microbiol. Infect. Dis., 34, 661, 10.1007/s10096-014-2296-3 · doi:10.1007/s10096-014-2296-3
- Ridley, 1996, 4-Aminoquinoline Analogs of Chloroquine with Shortened Side Chains Retain Activity against Chloroquine-Resistant Plasmodium falciparum, Antimicrob. Agents Chemother., 40, 1846, 10.1128/AAC.40.8.1846 · doi:10.1128/aac.40.8.1846
- Garcia, 2010, Malaria, Clin. Lab. Med., 30, 93, 10.1016/j.cll.2009.10.001 · DOI · Paper page
- Cross, 2010, Endochin Optimization: Structure-Activity and Structure-Property Relationship Studies of 3-Substituted 2-Methyl-4(1H)-Quinolones with Antimalarial Activity, J. Med. Chem., 53, 7076, 10.1021/jm1007903 · DOI
- Kurasawa, 2012, Quinolone Analogs 11: Synthesis of Novel 4-Quinolone-3-Carbohydrazide Derivatives with Antimalarial Activity, J. Heterocycl. Chem., 49, 288, 10.1002/jhet.774 · doi:10.1002/jhet.774
- Martins, 2016, Norfloxacin and N-Donor Mixed-Ligand Copper(II) Complexes: Synthesis, Albumin Interaction, and Anti-Trypanosoma cruzi Activity, Bioinorg. Chem. Appl., 2016, 5027404, 10.1155/2016/5027404 · doi:10.1155/2016/5027404
- Hiltensperger, 2016, Quinolone Amides as Antitrypanosomal Lead Compounds with In Vivo Activity, Antimicrob. Agents Chemother., 60, 4442, 10.1128/AAC.01757-15 · DOI
- Wang, 2012, Design, Synthesis and Evaluation of Clinafloxacin Triazole Hybrids as a New Type of Antibacterial and Antifungal Agents, Bioorgan. Med. Chem. Lett., 22, 5363, 10.1016/j.bmcl.2012.07.064 · DOI
- Mohamed, 2011, Ligational Behaviour of Lomefloxacin Drug towards Cr(III), Mn(II), Fe(III), Co(II), Ni(II), Cu(II), Zn(II), Th(IV) and UO2(VI) Ions: Synthesis, Structural Characterization and Biological Activity Studies, Spectrochim. Acta Part A Mol. Biomol. Spectrosc., 82, 8, 10.1016/j.saa.2011.05.089 · DOI
- Sultana, 2010, Synthesis, Characterization, Antibacterial, Antifungal and Immunomodulating Activities of Gatifloxacin–Metal Complexes, J. Mol. Struct., 969, 17, 10.1016/j.molstruc.2010.01.036 · doi:10.1016/j.molstruc.2010.01.036
- Debnath, 2015, Metal Complex of the First-Generation Quinolone Antimicrobial Drug Nalidixic Acid: Structure and Its Biological Evaluation, Appl Biochem Biotechnol, 175, 2659, 10.1007/s12010-014-1450-9 · doi:10.1007/s12010-014-1450-9
- Khamkhenshorngphanuch, T., Kulkraisri, K., Janjamratsaeng, A., Plabutong, N., Thammahong, A., Manadee, K., Na Pombejra, S., and Khotavivattana, T. (2020). Synthesis and Antimicrobial Activity of Novel 4-Hydroxy-2-Quinolone Analogs. Molecules, 25. · doi:10.3390/molecules25133059
- Xi, 2007, Helicases as Antiviral and Anticancer Drug Targets, Curr. Med. Chem., 14, 883, 10.2174/092986707780362998 · doi:10.2174/092986707780362998
- Portolani, 1988, Suppression of BK Virus Replication and Cytopathic Effect by Inhibitors of Prokaryotic DNA Gyrase, Antivir. Res., 9, 205, 10.1016/0166-3542(88)90004-6 · doi:10.1016/0166-3542(88)90004-6
- Koukoulaki, 2008, Impact of Prophylactic Administration of Ciprofloxacin on BK Polyoma Virus Replication, Transpl. Infect. Dis., 10, 449, 10.1111/j.1399-3062.2008.00334.x · doi:10.1111/j.1399-3062.2008.00334.x
- Ali, 2007, Inhibition of Simian Virus 40 Large T Antigen Helicase Activity by Fluoroquinolones, Antivir. Ther., 12, 1, 10.1177/135965350701200104 · doi:10.1177/135965350701200104
- Khan, 2012, Fluoroquinolones Inhibit HCV by Targeting Its Helicase, Antivir. Ther., 17, 467, 10.3851/IMP1937 · DOI
- Habtemariam, 2020, Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?, Arch. Med Res., 51, 733, 10.1016/j.arcmed.2020.05.024 · doi:10.1016/j.arcmed.2020.05.024
- Marciniec, 2020, Ciprofloxacin and Moxifloxacin Could Interact with SARS-CoV-2 Protease: Preliminary in Silico Analysis, Pharm. Rep., 72, 1553, 10.1007/s43440-020-00169-0 · DOI
- Tauber, 2008, Immunomodulatory Properties of Antibiotics, Curr. Mol. Pharm., 1, 68, 10.2174/1874467210801010068 · DOI
- Dalhoff, 2003, Immunomodulatory Effects of Quinolones, Lancet Infect. Dis., 3, 359, 10.1016/S1473-3099(03)00658-3 · DOI · Paper page
- Ogino, 2009, In Vivo and in Vitro Effects of Fluoroquinolones on Lipopolysaccharide-Induced pro-Inflammatory Cytokine Production, J. Infect. Chemother., 15, 168, 10.1007/s10156-009-0680-1 · DOI
- Zhang, 2008, Besifloxacin, a Novel Fluoroquinolone Antimicrobial Agent, Exhibits Potent Inhibition of pro-Inflammatory Cytokines in Human THP-1 Monocytes, J. Antimicrob. Chemother., 61, 111, 10.1093/jac/dkm398 · DOI
- Zusso, 2019, Ciprofloxacin and Levofloxacin Attenuate Microglia Inflammatory Response via TLR4/NF-KB Pathway, J. Neuroinflamm., 16, 148, 10.1186/s12974-019-1538-9 · DOI · Paper page
- Araujo, 2002, Effect of Moxifloxacin on Secretion of Cytokines by Human Monocytes Stimulated with Lipopolysaccharide, Clin. Microbiol. Infect., 8, 26, 10.1046/j.1469-0691.2002.00374.x · DOI
- Shalit, 2006, Anti-Inflammatory Effects of Moxifloxacin on IL-8, IL-1beta and TNF-Alpha Secretion and NFkappaB and MAP-Kinase Activation in Human Monocytes Stimulated with Aspergillus fumigatus, J. Antimicrob. Chemother., 57, 230, 10.1093/jac/dki441 · DOI
- Fabian, 2006, Moxifloxacin Enhances Antiproliferative and Apoptotic Effects of Etoposide but Inhibits Its Proinflammatory Effects in THP-1 and Jurkat Cells, Br. J. Cancer, 95, 1038, 10.1038/sj.bjc.6603355 · doi:10.1038/sj.bjc.6603355
- Batalha, 2016, Quinolones in the Search for New Anticancer Agents, Curr. Pharm. Des., 22, 6009, 10.2174/1381612822666160715115025 · doi:10.2174/1381612822666160715115025
- Beberok, 2018, Ciprofloxacin Triggers the Apoptosis of Human Triple-Negative Breast Cancer MDA-MB-231 Cells via the P53/Bax/Bcl-2 Signaling Pathway, Int. J. Oncol., 52, 1727
- Beberok, 2018, Ciprofloxacin-Mediated Induction of S-Phase Cell Cycle Arrest and Apoptosis in COLO829 Melanoma Cells, Pharmacol. Rep., 70, 6, 10.1016/j.pharep.2017.07.007 · DOI
- Nishi, 2017, Enoxacin with UVA Irradiation Induces Apoptosis in the AsPC1 Human Pancreatic Cancer Cell Line Through ROS Generation, Anticancer Res., 37, 6211
- Beberok, 2018, GSH Depletion, Mitochondrial Membrane Breakdown, Caspase-3/7 Activation and DNA Fragmentation in U87MG Glioblastoma Cells: New Insight into the Mechanism of Cytotoxicity Induced by Fluoroquinolones, Eur. J. Pharmacol., 835, 94, 10.1016/j.ejphar.2018.08.002 · DOI
- Patitungkho, 2011, Synthesis, Characterization and Anti-Tumor Activity of Moxifloxacin-Copper Complexes against Breast Cancer Cell Lines, Bioorgan. Med. Chem. Lett., 21, 1802, 10.1016/j.bmcl.2011.01.061 · doi:10.1016/j.bmcl.2011.01.061
- Nakai, 2017, Photodynamically-Induced Apoptosis Due to Ultraviolet A in the Presence of Lomefloxacin in Human Promyelocytic Leukemia Cells, Anticancer Res., 37, 6407
- Yadav, 2019, Repositioning of Fluoroquinolones from Antibiotic to Anti-Cancer Agents: An Underestimated Truth, Biomed. Pharmacother., 111, 934, 10.1016/j.biopha.2018.12.119 · DOI · Paper page
- Berninger, 2018, Fluorine Walk: The Impact of Fluorine in Quinolone Amides on Their Activity against African Sleeping Sickness, Eur. J. Med. Chem., 152, 377, 10.1016/j.ejmech.2018.04.055 · DOI
- Kraus, 2010, Second Generation Analogues of the Cancer Drug Clinical Candidate Tipifarnib for Anti-Chagas Disease Drug Discovery, J. Med. Chem., 53, 3887, 10.1021/jm9013136 · doi:10.1021/jm9013136
- Xu, 2019, Fluoroquinolone-Isatin Hybrids and Their Biological Activities, Eur. J. Med. Chem., 162, 396, 10.1016/j.ejmech.2018.11.032 · DOI
- Kljun, 2011, Physicochemical Studies and Anticancer Potency of Ruthenium H6-p-Cymene Complexes Containing Antibacterial Quinolones, Organometallics, 30, 2506, 10.1021/om101180c · DOI
- Regmi, 2007, Lack of Inhibitory Effects of Several Fluoroquinolones on Cytochrome P-450 3A Activities at Clinical Dosage in Dogs, J. Vet. Pharm., 30, 37, 10.1111/j.1365-2885.2007.00810.x · doi:10.1111/j.1365-2885.2007.00810.x
- Zhang, 2015, Synthesis and Anticonvulsant Activity Evaluation of 4-Phenyl-[1,2,4]Triazolo[4,3-a]Quinazolin-5(4H)-One and Its Derivatives, Arch. Pharm., 348, 564, 10.1002/ardp.201500115 · doi:10.1002/ardp.201500115
- Ukrainets, 2007, 4-Hydroxy-2-Quinolones 121. Synthesis and Biological Properties of 1-Hydroxy-3-Oxo-5,6-Dihydro-3h-Pyrrolo[3,2,1-Ij]Quino-Line-2-Carboxylic Acid Alkylamides, Chem. Heterocycl. Compd., 43, 856, 10.1007/s10593-007-0136-4 · doi:10.1007/s10593-007-0136-4
- Michot, 2005, Quinolones in 2005: An Update, Clin. Microbiol. Infect., 11, 256, 10.1111/j.1469-0691.2005.01131.x · DOI · Paper page
- Goa, 1997, Sparfloxacin. A Review of Its Antibacterial Activity, Pharmacokinetic Properties, Clinical Efficacy and Tolerability in Lower Respiratory Tract Infections, Drugs, 53, 700, 10.2165/00003495-199753040-00010 · doi:10.2165/00003495-199753040-00010
- Oliphant, 2002, Quinolones: A Comprehensive Review, Am. Fam. Physician, 65, 455
- Nicolau, 1992, Ofloxacin vs. Ciprofloxacin: A Comparison, Connect. Med., 56, 261
- Bidell, 2016, Fluoroquinolone-Associated Tendinopathy: Does Levofloxacin Pose the Greatest Risk?, Pharmacotherapy, 36, 679, 10.1002/phar.1761 · doi:10.1002/phar.1761
- Rubinstein, 2001, History of Quinolones and Their Side Effects, Chemotherapy, 47, 3, 10.1159/000057838 · DOI
- Haria, 1997, Trovafloxacin, Drugs, 54, 435, 10.2165/00003495-199754030-00006 · doi:10.2165/00003495-199754030-00006
- Cunha, 2001, Antibiotic Side Effects, Med. Clin. N. Am., 85, 149, 10.1016/S0025-7125(05)70309-6 · DOI · Paper page
- Stewardson, 2015, SATURN WP1 and WP3 Study Groups. Collateral Damage from Oral Ciprofloxacin vs. Nitrofurantoin in Outpatients with Urinary Tract Infections: A Culture-Free Analysis of Gut Microbiota, Clin. Microbiol. Infect., 21, 344.e1, 10.1016/j.cmi.2014.11.016 · DOI
- Fox, 2017, A Seven-Day Course of Trimethoprim-Sulfamethoxazole May Be as Effective as a Seven-Day Course of Ciprofloxacin for the Treatment of Pyelonephritis, Am. J. Med., 130, 842, 10.1016/j.amjmed.2017.01.025 · DOI
- Lee, 2014, Comparative Effectiveness of Different Oral Antibiotics Regimens for Treatment of Urinary Tract Infection in Outpatients: An Analysis of National Representative Claims Database, Medicine, 93, e304, 10.1097/MD.0000000000000304 · DOI
- Hooper, 2000, New Uses for New and Old Quinolones and the Challenge of Resistance, Clin. Infect. Dis., 30, 243, 10.1086/313677 · DOI · Paper page
- Kreling, 2020, Campylobacter Sp.: Pathogenicity Factors and Prevention Methods—New Molecular Targets for Innovative Antivirulence Drugs?, Appl. Microbiol. Biotechnol., 104, 10409, 10.1007/s00253-020-10974-5 · DOI
- Berning, 2011, Should Quinolones Come First in Helicobacter Pylori Therapy?, Ther. Adv. Gastroenterol., 4, 103, 10.1177/1756283X10384171 · doi:10.1177/1756283x10384171
- Wentzell, 2000, The Complex of DNA Gyrase and Quinolone Drugs on DNA Forms a Barrier to the T7 DNA Polymerase Replication Complex, J. Mol. Biol., 304, 779, 10.1006/jmbi.2000.4266 · DOI
- Willmott, 1994, The Complex of DNA Gyrase and Quinolone Drugs with DNA Forms a Barrier to Transcription by RNA Polymerase, J. Mol. Biol., 242, 351, 10.1006/jmbi.1994.1586 · DOI
- Drolet, M. (2018). DNA Topoisomerases as Targets for Antibacterial Agents. DNA Topoisomerases: Methods and Protocols, Springer. · DOI
- Ashley, 2017, Activities of Gyrase and Topoisomerase IV on Positively Supercoiled DNA, Nucleic Acids Res., 45, 9611, 10.1093/nar/gkx649 · DOI
- Sugino, 1977, Mechanism of Action of Nalidixic Acid: Purification of Escherichia coli NalA Gene Product and Its Relationship to DNA Gyrase and a Novel Nicking-Closing Enzyme, Proc. Natl. Acad. Sci. USA, 74, 4767, 10.1073/pnas.74.11.4767 · DOI · Paper page
- Forterre, 2009, Phylogenomics of DNA Topoisomerases: Their Origin and Putative Roles in the Emergence of Modern Organisms, Nucleic Acids Res., 37, 679, 10.1093/nar/gkp032 · DOI · Paper page
- Colgan, 2018, Negative Supercoiling of DNA by Gyrase Is Inhibited in Salmonella enterica Serovar Typhimurium during Adaptation to Acid Stress, Mol. Microbiol., 107, 734, 10.1111/mmi.13911 · DOI
- Kreuzer, 1979, Escherichia coli Mutants Thermosensitive for Deoxyribonucleic Acid Gyrase Subunit A: Effects on Deoxyribonucleic Acid Replication, Transcription, and Bacteriophage Growth, J. Bacteriol., 140, 424, 10.1128/jb.140.2.424-435.1979 · DOI · Paper page
- Khodursky, 1995, Topoisomerase IV Is a Target of Quinolones in Escherichia coli, Proc. Natl. Acad. Sci. USA, 92, 11801, 10.1073/pnas.92.25.11801 · DOI · Paper page
- Gellert, 1977, Nalidixic Acid Resistance: A Second Genetic Character Involved in DNA Gyrase Activity, Proc. Natl. Acad. Sci. USA, 74, 4772, 10.1073/pnas.74.11.4772 · DOI · Paper page
- Hooper, 1998, Bacterial Topoisomerases, Anti-Topoisomerases, and Anti-Topoisomerase Resistance, Clin. Infect. Dis., 27, S54, 10.1086/514923 · DOI · Paper page
- 1996, ParC Subunit of DNA Topoisomerase IV of Streptococcus pneumoniae Is a Primary Target of Fluoroquinolones and Cooperates with DNA Gyrase A Subunit in Forming Resistance Phenotype, Antimicrob. Agents Chemother., 40, 2252, 10.1128/AAC.40.10.2252 · DOI · Paper page
- Pan, 1996, Involvement of Topoisomerase IV and DNA Gyrase as Ciprofloxacin Targets in Streptococcus pneumoniae, Antimicrob. Agents Chemother., 40, 2321, 10.1128/AAC.40.10.2321 · DOI · Paper page
- Fournier, 2000, Selective Targeting of Topoisomerase IV and DNA Gyrase in Staphylococcus aureus: Different Patterns of Quinolone- Induced Inhibition of DNA Synthesis, Antimicrob. Agents Chemother., 44, 2160, 10.1128/AAC.44.8.2160-2165.2000 · DOI
- Ince, 2002, Dual Targeting of DNA Gyrase and Topoisomerase IV: Target Interactions of Garenoxacin (BMS-284756, T-3811ME), a New Desfluoroquinolone, Antimicrob. Agents Chemother., 46, 3370, 10.1128/AAC.46.11.3370-3380.2002 · DOI · Paper page
- Nilius, 2003, In Vitro Antibacterial Potency and Spectrum of ABT-492, a New Fluoroquinolone, Antimicrob. Agents Chemother., 47, 3260, 10.1128/AAC.47.10.3260-3269.2003 · DOI
- Markham, 2017, Delafloxacin: First Global Approval, Drugs, 77, 1481, 10.1007/s40265-017-0790-5 · doi:10.1007/s40265-017-0790-5
- Cambau, 2009, Target Specificity of the New Fluoroquinolone Besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli, J. Antimicrob. Chemother., 63, 443, 10.1093/jac/dkn528 · doi:10.1093/jac/dkn528
- Pham, 2019, Quinolone Antibiotics, Med. Chem. Commun., 10, 1719, 10.1039/C9MD00120D · DOI · Paper page
- Rotschafer, J.C., Andes, D.R., and Rodvold, K.A. (2016). Pharmacodynamics of Fluoroquinolones. Antibiotic Pharmacodynamics, Springer. · doi:10.1007/978-1-4939-3323-5
- Cuprys, 2018, Fluoroquinolones Metal Complexation and Its Environmental Impacts, Coord. Chem. Rev., 376, 46, 10.1016/j.ccr.2018.05.019 · DOI
- Dougherty, T.J., and Pucci, M.J. (2012). Fluoroquinolone Resistance: Mechanisms, Restrictive Dosing, and Anti-Mutant Screening Strategies for New Compounds. Antibiotic Discovery and Development, Springer. · DOI · Paper page
- Mustaev, 2014, Fluoroquinolone-Gyrase-DNA Complexes, J. Biol. Chem., 289, 12300, 10.1074/jbc.M113.529164 · DOI · Paper page
- Wohlkonig, 2010, Structural Basis of Quinolone Inhibition of Type IIA Topoisomerases and Target-Mediated Resistance, Nat. Struct. Mol. Biol., 17, 1152, 10.1038/nsmb.1892 · DOI · Paper page
- Malik, 2016, Suppression of Gyrase-Mediated Resistance by C7 Aryl Fluoroquinolones, Nucleic Acids Res., 44, 3304, 10.1093/nar/gkw161 · DOI
- Marians, 1997, Mechanism of Quinolone Action: A drug-induced structural perturbation of the DNA precedes strand cleavage by Topoisomerase IV, J. Biol. Chem., 272, 9401, 10.1074/jbc.272.14.9401 · doi:10.1074/jbc.272.14.9401
- Kampranis, 1998, The DNA Gyrase-Quinolone Complex. ATP Hydrolysis and the Mechanism of DNA Cleavage, J. Biol. Chem., 273, 22615, 10.1074/jbc.273.35.22615 · doi:10.1074/jbc.273.35.22615
- Drlica, 2009, Quinolones: Action and Resistance Updated, Curr. Top. Med. Chem., 9, 981, 10.2174/156802609789630947 · DOI · Paper page
- Hiasa, 2000, DNA Gyrase-Mediated Wrapping of the DNA Strand Is Required for the Replication Fork Arrest by the DNA Gyrase-Quinolone-DNA Ternary Complex, J. Biol. Chem., 275, 34780, 10.1074/jbc.M001608200 · doi:10.1074/jbc.m001608200
- Anderson, 1999, Quinolones Inhibit DNA Religation Mediated by Staphylococcus aureus Topoisomerase IV: Changes in drug mechanism across evolutionary boundaries, J. Biol. Chem., 274, 35927, 10.1074/jbc.274.50.35927 · DOI
- Laponogov, 2009, Structural Insight into the Quinolone-DNA Cleavage Complex of Type IIA Topoisomerases, Nat. Struct. Mol. Biol., 16, 667, 10.1038/nsmb.1604 · DOI · Paper page
- Chen, 1996, DNA Gyrase and Topoisomerase IV on the Bacterial Chromosome: Quinolone-Induced DNA Cleavage, J. Mol. Biol., 258, 627, 10.1006/jmbi.1996.0274 · doi:10.1006/jmbi.1996.0274
- Drlica, 2008, Quinolone-Mediated Bacterial Death, Antimicrob. Agents Chemother., 52, 385, 10.1128/AAC.01617-06 · DOI · Paper page
- Malik, 2007, Effect of Anaerobic Growth on Quinolone Lethality with Escherichia coli, Antimicrob. Agents Chemother., 51, 28, 10.1128/AAC.00739-06 · DOI
- Hong, 2019, Post-Stress Bacterial Cell Death Mediated by Reactive Oxygen Species, Proc. Natl. Acad. Sci. USA, 116, 10064, 10.1073/pnas.1901730116 · DOI · Paper page
- Baquero, 2021, Proximate and Ultimate Causes of the Bactericidal Action of Antibiotics, Nat. Rev. Microbiol., 19, 123, 10.1038/s41579-020-00443-1 · DOI · Paper page
- Luan, 2018, Suppression of Reactive Oxygen Species Accumulation Accounts for Paradoxical Bacterial Survival at High Quinolone Concentration, Antimicrob. Agents Chemother., 62, e01622-17, 10.1128/AAC.01622-17 · DOI
- Bhatnagar, K., and Wong, A. (2019). The Mutational Landscape of Quinolone Resistance in Escherichia coli. PLoS ONE, 14. · DOI
- Baker, 2013, Fitness Benefits in Fluoroquinolone-Resistant Salmonella Typhi in the Absence of Antimicrobial Pressure, eLife, 2, e01229, 10.7554/eLife.01229 · DOI
- Castro, 2020, The Genetic Background Modulates the Evolution of Fluoroquinolone-Resistance in Mycobacterium tuberculosis, Mol. Biol. Evol., 37, 195, 10.1093/molbev/msz214 · DOI
- Vergalli, 2020, Porins and Small-Molecule Translocation across the Outer Membrane of Gram-Negative Bacteria, Nat. Rev. Microbiol., 18, 164, 10.1038/s41579-019-0294-2 · DOI · Paper page
- Sousa, 2017, The Binding of Free and Copper-Complexed Fluoroquinolones to OmpF Porins: An Experimental and Molecular Docking Study, RSC Adv., 7, 10009, 10.1039/C6RA26466B · DOI
- Ferreira, 2015, Ciprofloxacin Metalloantibiotic: An Effective Antibiotic with an Influx Route Strongly Dependent on Lipid Interaction?, J. Membr. Biol., 248, 125, 10.1007/s00232-014-9749-6 · DOI
- Toro, 1990, Clinical Isolate of a Porinless Salmonella Typhi Resistant to High Levels of Chloramphenicol, Antimicrob. Agents Chemother., 34, 1715, 10.1128/AAC.34.9.1715 · DOI
- Karczmarczyk, 2011, Mechanisms of Fluoroquinolone Resistance in Escherichia coli Isolates from Food-Producing Animals, Appl. Environ. Microbiol., 77, 7113, 10.1128/AEM.00600-11 · DOI
- Rushdy, 2013, Contribution of Different Mechanisms to the Resistance to Fluoroquinolones in Clinical Isolates of Salmonella enterica, Braz. J. Infect. Dis., 17, 431, 10.1016/j.bjid.2012.11.012 · doi:10.1016/j.bjid.2012.11.012
- Mathur, 2016, Attenuation of in Vitro Host–Pathogen Interactions in Quinolone-Resistant Salmonella Typhi Mutants, J. Antimicrob. Chemother., 71, 111, 10.1093/jac/dkv299 · DOI
- Xie, 2016, RpoE Is a Putative Antibiotic Resistance Regulator of Salmonella enteric Serovar Typhi, Curr. Microbiol., 72, 457, 10.1007/s00284-015-0983-7 · DOI
- Vidovic, 2019, Molecular and Physiological Characterization of Fluoroquinolone-Highly Resistant Salmonella Enteritidis Strains, Front. Microbiol., 10, 729, 10.3389/fmicb.2019.00729 · doi:10.3389/fmicb.2019.00729
- Du, 2018, Multidrug Efflux Pumps: Structure, Function and Regulation, Nat. Rev. Microbiol., 16, 523, 10.1038/s41579-018-0048-6 · DOI · Paper page
- Attia, 2020, Fluoroquinolone Resistance Conferred by GyrA, ParC Mutations, and AbaQ Efflux Pump among Acinetobacter baumannii Clinical Isolates Causing Ventilator-Associated Pneumonia, Acta Microbiol. Immunol. Hung., 67, 234, 10.1556/030.66.2019.040 · DOI
- 2019, Mechanisms of Action and of Resistance to Quinolones, Antibiot. Drug Resist., 1, 39
- Martin, 2010, Constitutive SoxS Expression in a Fluoroquinolone-Resistant Strain with a Truncated SoxR Protein and Identification of a New Member of the MarA-SoxS-Rob Regulon, MdtG, Antimicrob. Agents Chemother., 54, 1218, 10.1128/AAC.00944-09 · DOI
- Oethinger, 1998, Overexpression of the MarA or SoxS Regulatory Gene in Clinical Topoisomerase Mutants of Escherichia coli, Antimicrob. Agents Chemother., 42, 2089, 10.1128/AAC.42.8.2089 · DOI · Paper page
- Sharma, 2017, The Multiple Antibiotic Resistance Operon of Enteric Bacteria Controls DNA Repair and Outer Membrane Integrity, Nat. Commun., 8, 1444, 10.1038/s41467-017-01405-7 · DOI
- Villagra, 2019, Cysteine Auxotrophy Drives Reduced Susceptibility to Quinolones and Paraquat by Inducing the Expression of Efflux-Pump Systems and Detoxifying Enzymes in S. Typhimurium, Biochem. Biophys. Res. Commun., 515, 339, 10.1016/j.bbrc.2019.05.122 · doi:10.1016/j.bbrc.2019.05.122
- Millanao, 2020, Inactivation of Glutamine Synthetase-Coding Gene GlnA Increases Susceptibility to Quinolones Through Increasing Outer Membrane Protein F in Salmonella enterica Serovar Typhi, Front. Microbiol., 11, 428, 10.3389/fmicb.2020.00428 · DOI
- Yeung, 2011, The Sensor Kinase CbrA Is a Global Regulator That Modulates Metabolism, Virulence, and Antibiotic Resistance in Pseudomonas Aeruginosa, J. Bacteriol., 193, 918, 10.1128/JB.00911-10 · DOI
200 of 305 shown
Cited by
Biofilms: Understanding the structure and contribution towards bacterial resistance in antibiotics
Shree, P., Singh, C. K., Sodhi, K. K., Surya, J. N., & Singh, D. K. (2023) · Medicine in Microecology · doi:10.1016/j.medmic.2023.100084 · Cited by 396
Hossain, T. J. (2024) · European Journal of Microbiology and Immunology · doi:10.1556/1886.2024.00035 · Cited by 392
Metadata
- Authors
- Millanao, A. R., Mora, A. Y., Villagra, N. A., Bucarey, S. A., & Hidalgo, A. A.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2021-11-25
- Volume
- 26
- Issue
- 23
- Pages
- 7153
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W3216313742
- Cited by
- 213
- References
- 4
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.